Helped by the introduction of new products, women’s health-care company Warner Chilcott (NASDAQ:WCRX) expects to book a fiscal 2011 profit in line with Wall Street estimates.
The specialty pharmaceutical company sees full-year earnings in the range of $3.45 to $3.55 a share, meeting average analyst estimates polled by Thomson Reuters of $3.50 a share.
Continue Reading Below
The Dublin-based company anticipates revenue in the range of $2.7 billion to $2.8 billion, in line with the Street’s view of $2.77 billion.
The outlook reflects its November warnings of a “dramatic decline” in sales of Actonel in Western Europe, partially offset by strong anticipated growth of promoted products in the U.S., including two launched last month.